Aviragen Therapeutics Inc Share Price Nasdaq
Equities
US0537611024
Biotechnology & Medical Research
Sales 2024 * | 14.73M 1.18B | Sales 2025 * | 23.1M 1.85B | Capitalization | 131M 10.47B |
---|---|---|---|---|---|
Net income 2024 * | -77M -6.17B | Net income 2025 * | -80M -6.41B | EV / Sales 2024 * | 8.86 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.65 x |
P/E ratio 2024 * |
-1.63
x | P/E ratio 2025 * |
-1.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Aviragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 31/12/03 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 18/12/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 24/10/19 |
Elaine Heron
BRD | Director/Board Member | 76 | 24/08/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
1st Jan change | Capi. | |
---|---|---|
+0.82% | 106B | |
+8.12% | 23.47B | |
-13.89% | 21.9B | |
-6.17% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B | |
+327.78% | 8.78B |